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ABSTRACT
Objective: To explore the circulation of anti-obesity
medicines via the internet and their quality.
Design: Cross-sectional study.
Setting: Internet pharmacies and pharmaceutical
suppliers accessible from Japan.
Participants: Anti-obesity medicines were purchased
using relevant keywords on Japanese Google search
engine. Blogs and advertisement-only sites were
excluded.
Primary and secondary outcome measures: The
authenticity of the samples was investigated in
collaboration with the manufacturers of the samples
and medicine regulatory authorities. Quality of the
samples was assessed by pharmacopoeial analyses
using high-performance liquid chromatography.
Results: 82 samples were purchased from 36 internet
sites. Approximately half of the sites did not mention
a physical address, and 45% of the samples did not
contain a package insert. A variety of custom
declarations were made for the shipments of the
samples: personal health items, supplement,
medicines, general merchandise, tea and others.
Among 82 samples, 52 samples were analysed to
check their pharmacopoeial quality. Authenticity
responses were received from only ﬁve of 20
manufacturing companies. According to the
pharmacopoeial analyses and authenticity
investigation, three of the samples were identiﬁed as
counterfeits and did not contain any active ingredients.
Two of these samples were conﬁrmed as counterfeits
by the manufacturer of the authentic products. The
manufacturer of the other sample did not respond to
our request for an authenticity check even after several
communication attempts. These counterfeit cases
have been reported at the rapid alert system of
Western Paciﬁc Region of the WHO.
Conclusions: Many counterfeit and unapproved anti-
obesity medicines may be easily bypassing regulatory
checks during shipping and are widely circulated
through the internet. Regulatory authorities should
take measures to prevent these medicines from
entering countries to safeguard their citizens.
INTRODUCTION
Over the past decade, the internet has
become an integral part of life for a variety of
uses. Approximately 60% of internet users in
some developed countries, such as Japan and
the USA, use the internet for their health-
related activities.
1e4 In fact, when internet
users were asked about speciﬁc searches
related to health, such as diet and ﬁtness
information or health insurance materials,
80% of the users among adult Americans in
a 2002 survey said that they had performed
these types of searches.
1 According to
a survey taken in Japan, a majority (86.3%) of
the medicines imported for personal use
were purchased through the internet.
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ARTICLE SUMMARY
Article focus
- Quality of online anti-obesity medicines.
- Circulation of unapproved anti-obesity medicines
via the internet.
Key messages
- Counterfeit and substandard anti-obesity medi-
cines, orlistat are identiﬁed.
- False and vague custom declarations were made
by some of the shipping companies to bypass
regulatory checks of unapproved online medi-
cines.
Strengths and limitations of this study
- Small sample size and low authenticity response
rate are limitations of this study.
- However, the study provides valuable informa-
tion for regulatory authorities on how unap-
proved and counterfeit medicines are being
circulated through the internet.
- Concerted efforts of authentic manufacturers and
medicine regulatory authorities are a must to
combat counterfeits and ensure access of quality
medicines to online consumers.
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Open Access ResearchHowever, according to the WHO, more than 50% of the
medicines from internet sites, which often conceal their
physical address, may be counterfeit or of substandard
quality.
6 The WHO deﬁnes counterfeit medicines as the
ones that are deliberately and fraudulently mislabelled
with respect to identity and/or source.
7e9 On the other
hand, substandard medicines are legitimate ones that do
not meet the quality speciﬁcations claimed by their
manufacturers.
10
A number of reports documented the severity of drug
counterfeiting during the past 2 decades. The WHO
found that 20%e90% of drugs were counterfeited in
some African countries.
11 12 In Tanzania, 12.2% of
antimalarials were identiﬁed as substandard in 2005.
13 In
2009, 37% of the samples did not meet standards in
Nigeria.
14 Similar evidences were also reported in
Asia.
15e17 The unprecedented growth of the internet
accompanied with globalisation of e-commerce might
have worsened the situation further.
18e20
Obesity is becoming a major public health epidemic in
this century and is associated with an increased risk for
a number of health problems, such as hypertension,
dyslipidaemia, type 2 diabetes and cardiovascular
diseases.
21 The prevalence of obesity and its associated
conditions are increasingly affecting developed and
developing countries over the past few decades.
22
Studies suggest that primarily adolescent and adult men
are overweight or obese in Japan.
23 Recommended
strategies for managing weight and obesity include life-
style changes with appropriate dietary management and
exercise. However, individuals with an isolated body mass
index of $30 or >27 kg/m
2 with comorbidities, such as
type 2 diabetes, cardiovascular diseases and obstructive
sleep apnoea, should receive pharmacotherapy as well.
24
Among the available anti-obesity medicines, phenter-
mine, diethylpropion and orlistat are approved by the
US Food and Drug Administration, but sibutramine has
been withdrawn from the market.
25 26 Of these anti-
obesity medicines, only mazindol has been approved for
use in Japan.
27 However, several of these anti-obesity
medicines are among those that are frequently imported
into Japan for personal use.
28 Safety proﬁle, risk versus
beneﬁt, cost-effectiveness of investment deter manufac-
turers and marketers to get interested in approving anti-
obesity medicines for Japanese market.
29
The online purchase of medicine through the internet
is a growing and convenient practice for many
consumers. This practice has also become one of the
most popular, easiest and safest routes for counterfeit
medicine traders.
6 30e32 The availability of counterfeit
erectile dysfunction (ED) medicines was reported in
Japan by a limited number of case investigations.
33 34 In
addition, a joint investigation done by four pharmaceu-
tical industries in Japan reported that approximately
60% of ED medicines available in the internet are
counterfeited.
34 However, the quality of anti-obesity and
diet medicines available through the internet was still
unknown. Since, all types of therapeutic classes of
medicines are counterfeited from essential medicines to
lifestyle drugs, an investigation was conducted to survey
the quality of anti-obesity medicines that were purchased
through online medicine sites. This investigation also
provided an understanding of the process by which
unapproved medicines are being imported for and used
by consumers in Japan.
METHODS
Study design
Quality of online anti-obesity medicines was assessed
using an online cross-sectional study during August
2009.
Selection of internet sites and sample collection
Internet sites were selected in ﬁve steps to purchase anit-
obesity medicines. In the ﬁrst step, the Japanese
keywords personal import agent (個人輸入代行), diet
(ダイエット) and obesity (肥満) were used on the
Japanese Google search engine (http://www.google.co.
jp). From a list of more than 140000 results, ﬁrst 500
were further screened out to ﬁnd online pharmacies or
suppliers or brokers that offer anti-obesity medicines,
provided that they did not mention their physical
address in their websites. Websites with physical address
and/or blogs and advertise-only sites were excluded in
this step. In the second through fourth steps, searches
were made on websites that advertise and sell counterfeit
Cialis (シアリス), Levitra (レビトラ) and Viagra (バイア
グラ). From our experiences on previous online medi-
cine studies, we presumed that the websites offer coun-
terfeit ED drugs and may also offer counterfeits of other
varieties of medicines.
5 35 As such, in the second step,
the Japanese keywords personal import agent (‘個人輸入
代行’) and Cialis (‘シアリス’), ‘50 mg’ and ‘100 mg’,
were used, and ﬁrst 100 results were further screened out
from a list of more than 35000. In the third step, the
keywords personal import agent (‘個人輸入代行’) and
Levitra (‘レビトラ’), ‘50 mg’ and ‘100 mg’, were used,
and again, ﬁrst 100 results were screened out from a list
of around 60000. The physical characteristics (eg,
colour of genuine and counterfeits, strength, packaging)
of original and counterfeit Cialis and Levitra were
identiﬁed earlier by the Ministry of Health, Japan.
33 In
the fourth step, samples were purchased from nine
internet sites where counterfeit Viagra (バイアグラ) was
offered in the past. The information on these sites was
provided by Pﬁzer. Finally, based on the information
available from our previous research, we searched home
pages of 10 domestic brokers, and four of them were
selected for sampling.
After the exclusion of blogs and advertisement-only
sites, 36 sites were chosen for the purchase of anti-obesity
medicines. A list of overweight/anti-obesity medicines
was sought on each of the selected sites. Available
medicines in the lists were numbered consecutively
according to their vertical or horizontal placement on
the web pages, excluding foods and drinks items. We
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in one of the selected sites. In the subsequent selected
websites, we purchased another brand or product of anti-
obesity medicines, which was listed ﬁrst.
Information on the site’s name, URL, compliance with
Japanese rules of ‘Act on Speciﬁed Commercial Trans-
action’ (ASCT), email address, the name of the product
and other information such as the dosage, efﬁcacy and
side effects, recommendation on consultation with
doctors or pharmacists or opportunities for consultation
were recorded while examining the sites from which at
least one product was purchased. ASCT is the policy
guidelines of all kinds of business transaction to protect
interests of the consumers in Japan. These guidelines
cover door-to-door sales, mail order sales, talemarketing,
and so on. According to the ASCT, all e-commerce sites
in Japan should mention their name, address(es), tele-
phone numbers, prices of commodities, shipment
procedure(s), and so on.
36
Observational analysis
All the samples were given distinct codes when the
shipments were received. The name of the product,
dosage form, content information from the printed
label, the manufacturers’ name and address, the country
of origin, the manufacture and expiration dates, lot,
registration and licence numbers, presence of package
insert and their languages, Japanese information/notes,
information from the shipping company, the sending
country, the date of shipment and arrival, and customs
declaration notations were recorded for each of the
samples.
Chemical analysis
Pharmacopoeial procedures for the analysis of the
samples (ie, orlistat, sibutramine, rimonabant,
benﬂuorex and lovastatin) were established and
performed using high-performance liquid chromatog-
raphy (HPLC), which are described brieﬂy below.
However, analytical methods and results of rhei rhubarb
and herbal products (ie, Pachyma hoelen, Ophiopogonis
tuber and dai dai hua) were excluded since they will be
reported elsewhere.
Preparation of the sample solutions
Randomly selected capsules of orlistat and sibutramine
samples were weighed accurately. After each capsule was
weighed, the contents were removed, and the empty
capsule shells were subsequently weighed. The differ-
ence between the weight of the whole capsule and the
capsule shell was assumed to be the weight of the
contents. To prepare sample solutions of lovastatin,
benﬂuorex and rimonabant tablets, randomly chosen
tablets were weighed accurately and subsequently
crushed separately into powder. Approximately 80 ml of
methanol was added to the capsule’s contents or tablet
powder, and the mixture was sonicated for 30 min. After
sonication, methanol was then added to a volume of
100 ml. The resulting solutions were ﬁltered through
a membrane ﬁlter (pore size: 0.45 mm) and used as the
sample solutions.
Preparation of standard solutions
Three consecutive strengths of standard solutions were
prepared by dissolving 0.375, 0.75 and 1.50 mg of orli-
stat; 0.050, 0.100 and 0.200 mg of sibutramine; 0.100,
0.200 and 0.500 mg of lovastatin; 0.100, 1.50 and 2.00 mg
of benﬂuorex; 0.100, 0.200 and 0.500 mg of rimonabant
in 1 ml of methanol for each solution.
Assay condition
Ten microlitres of each sample solution and standard
solution was placed in phials and assayed using a photo-
diode array of 225 nm wavelength (200e400 nm range
for spectra) with a stainless steel column with a 4.6 mm
internal diameter and 15 cm length packed with octa-
decylsilanized silica gel for liquid chromatography (5 mm
particle diameter) used with Mightysil RP-18 GP 150-4.6.
The column temperature was maintained at 458C. A
mixture of methanol and phosphate buffer, pH 7.0
(17:3), was used as the mobile phase at a ﬂow rate of
1.2 ml/min.
Authenticity investigation
A catalogue and a questionnaire for all the samples were
created that included the information from the printed
labels of the product packages. The printed information
was also checked against the information on the manu-
facturers’ websites. The questionnaires were sent to the
appropriate manufacturers with a portion of the samples
for veriﬁcation of their authenticity. The regulatory
authorities for medicine in the country of origin were
also contacted to verify the legitimacy of the products
and their approval for marketing. After considering the
WHO deﬁnition of counterfeit medicines, the gathered
information was analysed to determine the authenticity
of the individual samples and their manufacturers.
7 37
Statistical analysis
Because of the small size of the sample, descriptive
statistical analysis was performed using Microsoft Excel.
RESULTS
In the ﬁrst step of the internet search, 15 sites were
selected that did not show a physical address. In the
second through fourth steps, six, two and nine of the
websites were selected that concurrently advertised
counterfeit Cialis, Levitra and Viagra, respectively. Two
of the sites with fake Cialis and Viagra also did not show
a physical address. Four of the websites were hosted by
domestic shipping companies selected in the ﬁfth step. A
total of 82 samples from 31 varieties of anti-obesity
products were purchased from 36 internet sites (table 1).
On average, these sites offered 62 kinds of products
(including diet foods and drinks). Some of these prod-
ucts were shipped in divided shipments and treated as
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Quality of online anti-obesity medicinesdistinct samples. However, only one of such identical
samples was analysed for pharmacopoeial quality.
Information available on the websites
Different levels of compliance with ASCT were observed
throughout all (36) the websites.
36 For instance, all
(100%) of them mentioned the selling price, shipping
charges for the goods and methods of payment.
However, only 21 (58.3%) of them provided telephone
numbers, and only 17 (47.2%) of them mentioned
a physical address.
Information for email addresses and shipment proce-
dures were presented on all the selected sites. However,
only 21 (58.3%) of them encouraged consumers to
consult with a physician or pharmacist. Consultation
services were available at two (5.5%) of the sites. Dosage
and administration, effects and efﬁcacy, and side effects
related to the products were explained in 18 (50%), 23
(63.8%) and 17 (47.2%) of the sites, respectively, despite
the prohibition on advertisements for unapproved
medicines.
Information provided with the samples
On examination of the printed materials, the languages
of the package inserts were found to be in English for 14
(17.1%) of the samples, Chinese for 13 (15.9%),
both Chinese and Korean for 10 (12.2%), both English
and Chinese for four (4.9%), Turkish for two (2.4%),
both English and Thai for one (1.2%), and English,
Chinese and Russian for one (1.2%) of the samples.
However, 37 (45.1%) of the samples did not have any
package inserts.
Shipment of the samples
Samples were sent by 29 different shipping companies.
The majority (13 companies) shipped from China, and
the second largest group was from India (four compa-
nies). Others were shipped from the USA (three), Japan
(two), Thailand (two), Switzerland (one), Hong Kong
(one), Cambodia (one), the Fiji Islands (one) and
Puerto Rico (one). The customs declaration was ‘health
product/personal health items’ for 20 (24.4%) of the
samples, ‘supplement’ for 13 (15.9%) of the samples,
‘medicine’ for 10 (12.2%) of the samples and the actual
name of the product in two (2.4%) cases. However, 12
(14.7%) of the samples were shipped with a declaration
of general merchandise and/or tea, 11 (13.4%) of them
declared ‘other’ and 14 (17.1%) of them did not
mention anything as the declaration. Interestingly, one
representative from an importing agent of a diet medi-
cine clinic (Sabairato Yanhee and MD Clinic, http://
www.gop23.com/, accessed 27 October 2011) enquired
over the telephone regarding the purpose for our
purchase of the medicine and asked if we had any rela-
tionship with the Ministry of Health and Labour Welfare,
Japan; they did not sell their products to us.
Sample characteristics
Of the 82 samples, 42 (51.2%) were advertised on the
websites as containing sibutramine hydrochloride and 15
(18.3%) were advertised as orlistat. Rimonabant,
benﬂuorex and lovastatin were advertised to be in two
(2.4%) of the samples. Rhei rhubarb was said to be in
one, and the remaining 18 (21.9%) samples were
advertised to be herbal products (table 1). All these
products were advertised by their brand names. Of the
64 synthetic products, 58 samples from 19 different
products were prescription medicines; however, none of
which requested a prescription for the purchase. Five
brands of orlistat were over-the-counter medicines, and
one sample, dai dai hua, was marketed as a natural
supplement. Interestingly, dai dai hua was advertised as
sibutramine by its agent, and the sample actually
contained sibutramine as shown by chemical analysis.
According to purported country of marketing author-
isation holder, 25 sibutramine products originated from
India (dispatched from India, Hong Kong and Fiji
Islands), seven from China (dispatched from China),
seven from Germany (dispatched from Hong Kong and
Cambodia) and three from Hong Kong (dispatched
from Cambodia). Among 15 orlistat products, seven
originated from India (dispatched from India and
Japan), ﬁve from the UK (dispatched from Switzerland,
the USA and Japan), two from Switzerland (dispatched
Table 1 Active ingredient
Active ingredient Approval status in Japan n (%) Classiﬁcation
Sibutramine hydrochloride Not approved 42 (51.2) Prescription medicine
Orlistat Not approved 15 (18.3) Prescription medicine: 10
Over the counter: 5*
Rimonabant Not approved 2 (2.4) Prescription medicine
Benﬂuorex Not approved 2 (2.4) Prescription medicine
Lovastatiny Not approved 2 (2.4) Prescription medicine
Pachyma hoelen ( ) Approved 14 (17.1) Over the counter
Ophiopogonis tuber ( ) Approved 3 (3.6) Over the counter
Rhei rhubarb ( )y Approved 1 (1.2) Over the counter
Dai dai hua ( ) Approved 1 (1.2) Over the counter
Total 82 (100.0)
*Alli (orlistat 60 mg).
yAvailable under diet (ダイエット) search/not classiﬁed as anti-obesity medicines.
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from Thailand). Two rimonabant, two benﬂuorex and
one lovastatin samples originated from India
(dispatched from Thailand and Japan), France
(dispatched from Hong Kong) and the USA (dispatched
from the USA), respectively. All herbal products
(including dai dai hua) originated from China, except
two (ie, Pachyma hoelen), which are from the USA,
however, dispatched from China.
Quality analysis
Of total, 52 samples (ie, sibutramine: 21, orlistat: 13,
rimonabant: 2, benﬂuorex: 2, lovastatin: 1 and herbal
products: 13) were analysed by HPLC to measure
quantity of active ingredients in the samples. Thirty
samples (received in divided shipments and identical to
an analysed sample from a same source, respectively)
were excluded because of the insufﬁcient materials.
Quantitative analysis by HPLC showed that all (21) the
samples of sibutramine were in the acceptable range
(90%e110%), except one (mean content percentage of
60.267.6). No active ingredient was detected in three of
the 13 samples of orlistat that we tested (ﬁgure 1). These
three samples were identiﬁed to be counterfeit. Of these
three counterfeit samples, two were found to be Xenical
after analysis by the researchers and the manufacturer of
the genuine products. No active ingredient was detected
in the last sample, only starch (ﬁgure 1). The other
counterfeit sample contained unknown excipients.
None of the samples of lovastatin, benﬂuorex or rimo-
nabant failed the HPLC analysis.
Authenticity investigation
Responses to our requests for authentication were
received from only ﬁve of the 20 manufacturing
companies of the genuine samples. According to the
responses that we received, all the responding manu-
facturers were Good Manufacturing Practice (GMP)
compliant. Of the 12 reported samples, two of the orli-
stat samples (Xenical) from the same manufacturer were
conﬁrmed to be counterfeit (table 2).
The counterfeit samples were purchased at http://
www.kenkoclinic.com and sent to us from Puerto Rico.
They bore the same manufacture and expiration dates
(MFD: 02-2011 and EXP: 02-2011, ﬁgure 2) on their
blisters, which had not yet occurred at the time of our
investigation. The printed information on the blisters of
the counterfeits was a different colour with a similar but
slightly different logo (ﬁgure 3).
Telephone communications were made to the manu-
facturer of Zenigal (orlistat 120 mg) in India, which did
not contain any of the active ingredients that had been
claimed on the product labels. However, the manufac-
turer did not respond after several communication
attempts. This counterfeit Zenigal sample was sent to us
from Japan. We reported that these three cases of
counterfeit medicines at the rapid alert system of the
Western Paciﬁc Region of the WHO.
Responses were received from the medical regulatory
authorities of three countries (Germany, Switzerland and
the USA) for ﬁve of the manufacturers. Their responses
stated that only orlistat has approval to be manufactured
in Switzerland. Approval for the manufacture of
Figure 1 Chromatograms (AeD) of the reference standard of orlistat and counterfeit samples.
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and it was not approved for use in the USA.
DISCUSSION
Provided information on the samples
According to the Pharmaceutical Affairs Law (PAL) in
Japan, advertising of unapproved medicines is
prohibited, and customs should seize any shipment of
prescription medicines when the amount exceeds more
than a 1-month dose or any non-prescription medicines
that exceed more than a 2-month dose. However, at least
some of the samples in this study that exceeded the
approved amount for shipment made it through the
regulatory checks during shipping.
38 Surprisingly, at
least four of the shipping companies are conducting
business in Japan. Contact information was not provided
on many of the sites (52.8%), which seemingly contra-
dicts ASCT.
36 According to our study, nearly 50% of the
sites mentioned dosage administration, effects or side
effects of the medicines, which are not permitted by the
PAL in Japan.
38 As found in many previous studies on
e-medicines, approximately 50% of the samples did not
contain a package insert.
35 39e42 Moreover, several of the
weight loss products may contain harmful or contra-
indicated ingredients.
33 39 Similar to the ﬁndings of
a recent study, none of the websites of our study required
a prescription to purchase medicines.
43 44
Approval status of the products
The majority of the study samples were sibutramine,
which is a selective inhibitor of the central neuronal
reuptake of serotonin and norepinephrine and reduces
food intake and body weight.
45 However, after conclu-
sion of the safety review of sibutramine, the European
Medicines Agency has suspended its marketing author-
isation in the European Union (EU).
46 A recently
published study reported that generic Figurer (sibutr-
amine 10 mg), even though it has not been reviewed by
the responsible government (the USA, the exporting
nation), is freely circulating via the internet, which is
a serious concern for public health.
35 According to the
medicine regulations of Hong Kong, Figurer does not
need manufacturing authorisation because the medicine
is manufactured in a foreign country. The authorisation
status of Alli (orlistat 60 mg) as a prescription medicine
has been recommended to transition to a non-prescrip-
tion medicine in the EU.
47 In a questionnaire conducted
by community pharmacists in Great Britain, orlistat is
suspected to be misused by consumers, as stated in their
responses.
48 Similarly, marketing authorisation for
Acomplia (rimonabant) has also been withdrawn in the
EU in January 2009, and safety proﬁles of other anti-
obesity agents are generating controversy in different
parts of the world.
49e53 Even though all the anti-obesity
agents sampled in this survey are unapproved in Japan, it
is possible that anyone can procure these items without
declaring the actual contents during shipping.
Authenticity and quality of the samples
As similarly shown in previous studies, we observed low
rates of authenticity.
54 Responses from only ﬁve (25%) of
Table 2 Results of authenticity investigation
Active ingredient
Labelled country of
marketing authorisation holder Genuine sample Counterfeit sample
Manufacturing
licence
Orlistat (60 mg) USA 5 0 Yes
Benﬂuorex (150 mg) France 2 0 Yes
Rimonabant (20 mg) India 1 0 Yes
Orlistat (120 mg) Switzerland 1 2 Yes
Rhei rhubarb China 1 0 Yes
Orlistat* (120 mg) India 0 1 Unknown
*Labelled manufacturer did not reply.
Figure 2 Front of blister: (A) genuine sample, (B) counterfeit
sample, (C) manufacturing date of counterfeit sample (MFD
02-2011), and (D) expiration date of counterfeit sample (EXP
02-2011).
Figure 3 Reverse side of blister: (A) logo of genuine sample
and (B) logo of counterfeit sample.
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Quality of online anti-obesity medicinesthe manufacturers for 14.6% of the samples were
received. The counterfeit samples identiﬁed in this
survey were conﬁrmed by the manufacturer of the
corresponding genuine products. Counterfeiting of anti-
obesity medicines, particularly orlistat, has been previ-
ously reported.
55 56 Based on the external characteristics
of the counterfeits, these products most often differ in
their printed information, design, colour, and so on
from those of the genuine drugs.
17 57 As shown in some
other studies, the counterfeits detected in this survey did
not contain any active ingredients.
54 58 It is not clear why
the manufacture of Zenigal, which failed the content
analysis, did not respond to our authentication request.
In such a case, it can be assumed that the manufacturer
is already aware of the distribution of low-quality prod-
ucts in the pharmaceutical market. Several reports
suggest that patients have sought medical treatment for
life-threatening complications after the consumption of
fake or substandard medicines purchased online.
59
When products are purchased through the internet and
the sites are not sufﬁciently regulated, customers are left
to accept the consequences.
According to the PAL, a person violating pharmaceu-
tical regulation may be sentenced to an imprisonment of
up to 3 years or imposed a penalty of up to JPU 3 million
or both.
60 In case of such violation by a company, the
penalty may be increased to a maximum JPU 100
million.
60 Nevertheless, PAL has only jurisdiction to
regulate domestic traders and has no hold on foreign
online traders. Strengthening international collabora-
tion along with publiceprivate partnership initiatives
may facilitate stemming out illegal internet trading
hosted from outside national boundaries.
19 61 62
One of the limitations of the study might be small
sample size, which may restrict study ﬁndings to Japan.
The sampling scheme may also limit our ﬁndings from
generalisation to all internet sites. However, the
sampling scheme was purposefully designed to investi-
gate suspicious online medicine sites. Our study was not
designed comprehensively to explore information
during shipment of medicinal products, especially at
Japanese custom check. Further evaluation with a repre-
sentative sample may provide more information on the
extent of the problem. Low response rate of authenticity
investigation may also be considered as a limiting factor.
However, better communication and cooperation
among authentic manufacturers and medicine regula-
tory authorities may increase response rate and generate
more information to counteract against counterfeits.
CONCLUSIONS
It is evident from this study that counterfeit, unapproved
and suspended anti-obesity medicines, are circulating via
the internet. Because of gaps and the insufﬁcient
monitoring system of imports for personal use in the
rapidly growing e-commerce environment, these medi-
cines can easily enter into the distribution channels for
pharmaceuticals and may pose health hazards for
consumers. Time has come to address such gaps of cross-
border pharmaceutical e-commerce and regulate the
same through international cooperation and publice
private partnerships. Obviously, ﬁrst and foremost step
should be at country levels to make necessary amend-
ments of existing regulation focusing online pharma-
ceutical transactions. Furthermore, there might be an
urgent need at international level to formulate common
regulation and agreements focusing issues of pharma-
ceutical e-commerce.
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